|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Urology |
|
Laboratory Address |
Dept Urology, Akita University Graduate School of Med., 1-1-1 Hondo, Akita 010-8543, Japan |
|
Laboratory Phone number |
+81-18-884-6154 |
|
Laboratory Fax number |
+81-18-836-2619 |
|
Homepage URL |
HABUCHI Tomonori
|
|
|
Research Interests 【 display / non-display 】
-
泌尿器腹腔鏡手術
-
Oncology
-
Laparoscopic Surgery
-
Robotic Surgery
-
Urology
Graduating School 【 display / non-display 】
-
-1986.03
Kyoto University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-1997.09
Kyoto University Graduate School,Division of Medicine Doctor's Course Accomplished credits for doctoral program
Campus Career 【 display / non-display 】
-
2009.04-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Professor
Research Achievements 【 display / non-display 】
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Yoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, Takuma Narita, Toshikazu Tanaka, Yuki Miura, Daichi Sasaki, Daisuke Noro, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Takahiro Yoneyama, Yasuhiro Hashimoto, Tomonori Habuchi, Chikara Ohyama
BJUI compass ( BJUI Compass ) 3 ( 2 ) 154 - 161 2022.03
Research paper (journal)
OBJECTIVE: To evaluate the effects of the concomitant use of proton pump inhibitors (PPIs) and/or antibiotics (Abs) on oncological outcomes in patients with advanced urothelial carcinoma. PATIENTS AND METHODS: We retrospectively evaluated 155 patients with advanced urothelial carcinoma who were treated with immune checkpoint inhibitors (ICIs) between August 2015 and April 2021. The concomitant use of PPI or Abs was defined as any PPI or Abs administered within 30 days before ICI initiation and during ICI therapy. The primary outcomes were the effect of PPI and/or Abs use on the objective response rate (ORR) and immune-related adverse events (irAEs). The secondary outcomes were the effects of PPI and/or Abs use on progression-free survival (PFS) and overall survival (OS) after ICI therapy analyzed using the inverse probability of treatment weighting-adjusted Cox regression analysis. RESULTS: Of the 155 patients enrolled in the study, 99 (64%) were PPI users and 56 (36%) Abs users. PPI users were associated with a significantly poorer ORR than non-PPI users (41% vs. 20%, respectively), whereas Abs use was not significantly associated with changes in ORR. The rate of irAEs was not significantly associated with the use of PPIs or Abs. Multivariate inverse probability of treatment weighting-adjusted Cox regression analysis revealed significantly poorer PFS and OS in PPI users than in non-PPI users, whereas Abs use was not associated with poorer outcomes. CONCLUSION: The concomitant use of PPI may adversely affect oncological outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with ICI therapy.
-
Robotic-assisted laparoscopic partial nephrectomy for renal cell carcinoma in horseshoe kidney: a hybrid technique with conventional laparoscopic surgery.
Kazuyuki Numakura, Yumina Muto, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Tomonori Habuchi
International cancer conference journal 9 ( 4 ) 199 - 202 2020.10
Research paper (journal)
Robotic-assisted laparoscopic partial nephrectomies (RAPN) have come up to standard treatment for small renal tumors, with a growing indication to accomplish this procedure. Although a horseshoe kidney is one of the most common congenital renal fusion anomalies, surgical planning for tumors is considered difficult because of its poor mobility and abnormal vascular supply. We showed our experience of RAPN in combination with conventional laparoscopic kidney mobilization and dissection for a patient with renal cell carcinoma in a horseshoe kidney. The patient was an otherwise healthy 66-year-old man with 26 mm right renal mass on the lower pole of the horseshoe kidney. Robotic assistance allows for proper tissue dissection, easy to aware unconfirmed vasculatures, and meticulous fine suturing and would overcome the potential challenges involved in the minimally invasive management of such complex anomalies as shown in the patient.
-
Altered miRNA expression in high-fat diet-induced prostate cancer progression.
Taketoshi Nara, Shintaro Narita, Huang Mingguo, Toshiaki Yoshioka, Atsushi Koizumi, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
Carcinogenesis 37 ( 12 ) 1129 - 1137 2016.12
Research paper (journal)
Recent evidence suggests that a high-fat diet (HFD) plays an important role in prostate carcinogenesis; however, underlying mechanisms largely remain unknown. Here, we investigated microRNA (miRNA) expression changes in murine prostate cancer (PCa) xenografts using two different diets: HFD and control diet. We then assessed the roles and targets of altered miRNAs in HFD-induced PCa progression. We identified 38 up- and 21 downregulated miRNAs in xenografts under HFD conditions using the miRCURY LNA™ microRNA array. The differences in 10 candidate miRNAs were validated using quantitative RT-PCR. We focused on miR-130a because the expression levels were significantly lower in the three PCa cell lines in comparison with benign prostate PINT1B cells. PCa cells cultured in a medium containing HFD mouse serum were associated with significantly higher cell proliferation rates and lower miR-130a expression levels. Further, miR-130a modulated MET expression in PCa cells, and MET was overexpressed in in vitro and in vivo HFD-induced PCa progression models. Moreover, ectopic miR-130a downregulated AR in LNCaP cells and DICER1 in PC-3 and DU145 cells, respectively. In human tissues, as elucidated using laser capture microdissection, the mean miR-130a expression level in cancer epithelium was significantly lower than that in normal epithelium. Furthermore, cytoplasmic MET in PCa tissues was overexpressed in patients with higher body mass index. In conclusion, a substantial number of miRNAs was altered in HFD-induced PCa growth. Specifically, miR-130a was attenuated in HFD-induced PCa progression with MET overexpression. miRNAs thus have implications in the mechanism, prevention and treatment of HFD-induced PCa progression.
-
Efficacy and safety of bladder hydrodistension for decreased bladder capacity induced by intravesical BCG therapy.
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi
Scandinavian journal of urology 50 ( 6 ) 429 - 432 2016.12
Research paper (journal)
OBJECTIVE: Intravesical BCG therapy is widely used for the treatment of high-risk, non-muscle-invasive bladder cancer. Among various reported side-effects, decreased bladder capacity is a serious side-effect that significantly worsens patients' quality of life. This article reports the efficacy and safety of bladder hydrodistension (BHD) in six patients with seriously decreased bladder capacity caused by BCG treatment. METHODS: Six patients with low bladder capacity (<100 ml in voiding diaries) and complaint of grade 3 irritative symptoms were diagnosed with decreased bladder capacity and treated with BHD. Alleviation of symptoms was defined as medication being discontinued or reduced after BHD. RESULTS: Five patients were male and one was female, and the mean age was 67.7 years. The mean interval between the last transurethral resection and BCG therapy was 26.0 days. Before BHD, all patients had been treated with antibiotics, anticholinergics and non-steroidal anti-inflammatory drugs (NSAIDs). The median bladder capacity before treatment was 40 ml (range 30-100 ml), and the median capacity increased to 200 ml (175-250 ml) within 2 weeks following BHD therapy. Four patients stopped NSAID use and three patients stopped anticholinergic use. One patient needed total cystectomy for recurrent symptoms. With a median follow-up period of 32 months, the bladder capacity remained stable without symptomatic deterioration in the remaining five patients. There was neither tumor spread nor disseminated tuberculosis infection. CONCLUSIONS: BHD appears to be an effective treatment option in patients with severely decreased bladder capacity. Its efficacy and safety were acceptable.
-
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I Rini, Ying Chen, Angel H Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Japanese journal of clinical oncology 46 ( 11 ) 1031 - 1041 2016.11
Research paper (journal)
OBJECTIVES: To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma. METHODS: The data included 44 Japanese and 169 non-Japanese treatment-naïve patients with metastatic renal cell carcinoma. Patients received twice-daily axitinib 5 mg during a 4-week lead-in period. Patients who met the pre-defined randomization criteria were stratified by Eastern Cooperative Oncology Group performance status and randomly assigned (1:1) to axitinib or placebo titration. The primary endpoint was objective response rate; secondary endpoints included progression-free survival and safety. Predictive factors were analyzed using data from all patients. RESULTS: The objective response rate (95% confidence interval) was 66% (50-80%) vs. 44% (36-52%) in Japanese and non-Japanese patients, respectively. At the primary analysis, median progression-free survival could not be estimated for Japanese patients, and was 27.6 months (95% confidence interval: 16.6-33.2) in an updated analysis. Hypertension, diarrhea, hand-foot syndrome, dysphonia, hypothyroidism and proteinuria were common adverse events in Japanese patients. Due to a small number of randomized patients, effects of axitinib dose titration could not sufficiently be confirmed among Japanese patients. The multivariate analysis identified time from histopathological diagnosis to treatment and sum of the longest diameter for target lesion at baseline as independent predictive factors for progression-free survival. CONCLUSIONS: Axitinib is effective and well tolerated as first-line metastatic renal cell carcinoma therapy in Japanese patients. Predictive factors for axitinib efficacy endpoints identified in this setting warrant further investigation.
-
BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)
沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP08 - 03 2023.04
-
ラード食による前立腺癌発症・増殖における腸内細菌環境の解析(Specific Gut Microbial Environment in Lard Diet-Induced Prostate Cancer Development and Progression)
佐藤 博美, 成田 伸太郎, 石田 雅宣, 高橋 佳子, 黄 明国, 嘉島 相輝, 山本 竜平, 小泉 淳, 奈良 健平, 沼倉 一幸, 齋藤 満, 吉岡 年明, 羽渕 友則
日本癌学会総会記事 ( (一社)日本癌学会 ) 81回 J - 3038 2022.09
-
細胞質内におけるコネキシン43の発現が腎細胞癌の予後に与える影響(High expression of Connexin 43 in cytoplasm relates to worse clinical outcomes in patients with renal cell carcinoma)
小林 瑞貴, 大森 泰文, 沼倉 一幸, 関根 悠哉, 武藤 弓奈, 成田 伸太郎, 羽渕 友則
日本癌学会総会記事 ( (一社)日本癌学会 ) 81回 P - 3190 2022.09
-
A Case of Renal Anastomosing Hemangioma
SASAKI Yoshiki, KASHIMA Soki, KOYAMA Takashi, HIROSHIMA Yuko, AMANO Kenji, TAKAHASHI Syuhei, NARA Taketoshi, KOIZUMI Atsushi, YAMAMOTO Ryohei, NUMAKURA Kazuyuki, SAITO Mitsuru, NARITA Shintaro, NANJO Hiroshi, SATOH Shigeru, HABUCHI Tomonori
68 ( 8 ) 265 - 269 2022.08
-
Robot-assisted laparoscopic surgery for retroperitoneal and pelvic endocrine tumors
Nara Taketoshi, Numakura Kazuyuki, Habuchi Tomonori
Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery ( Japan Association of Endocrine Surgeons・Japanese Society of Thyroid Surgery ) 39 ( 1 ) 44 - 48 2022
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Molecular mechanisms and target molecules associated with progression and treatment resistance of urologic cancers associated with microbiome alterations by diet and obesity
Grant-in-Aid for Scientific Research(B)
Project Year： 2021.04 - 2025.03
-
Grant-in-Aid for Scientific Research(A)
Project Year： 2016.04 - 2021.03 Investigator(s): Habuchi Tomonori
-
Grant-in-Aid for Scientific Research(A)
Project Year： 2015.04 - 2020.03 Investigator(s): Ohyama Chikara
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2015.04 - 2019.03 Investigator(s): Saito Mitsuru, Habuchi Tomonori, Satoh Shigeru, Nanjo Hiroshi, Inoue Takamitsu, Yamamoto Ryohei, Mitobe Yoko
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2015.04 - 2018.03 Investigator(s): Mitsuzuka Koji, KYAN Atsushi, SATO Tomonori, ORIKASA Kazuhiko, MIYAZATO Minoru, AOKI Hiroshi, NARITA Shintaro, KOIE Takuya, TOCHIGI Tatsuo, HABUCHI Tomonori, OHYAMA Chikara